메뉴 건너뛰기




Volumn 31, Issue 6, 2016, Pages 906-914

Cerebrospinal fluid biomarkers and clinical features in leucine-rich repeat kinase 2 (LRRK2) mutation carriers

Author keywords

Alpha synuclein; Biomarker; CSF; LRRK2; Parkinson

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; DOPAMINE TRANSPORTER; HEMOGLOBIN; LEUCINE RICH REPEAT KINASE 2; TAU PROTEIN; AMYLOID BETA-PROTEIN (1-42); BIOLOGICAL MARKER; LRRK2 PROTEIN, HUMAN; PEPTIDE FRAGMENT;

EID: 84963799520     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26591     Document Type: Article
Times cited : (20)

References (41)
  • 1
    • 79953283868 scopus 로고    scopus 로고
    • Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression
    • Shi M, Bradner J, Hancock AM, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 2011;69(3):570-580.
    • (2011) Ann Neurol , vol.69 , Issue.3 , pp. 570-580
    • Shi, M.1    Bradner, J.2    Hancock, A.M.3
  • 2
    • 84885699313 scopus 로고    scopus 로고
    • Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease
    • Kang JH, Irwin DJ, Chen-Plotkin AS, et al. Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol 2013;70(10):1277-1287.
    • (2013) JAMA Neurol , vol.70 , Issue.10 , pp. 1277-1287
    • Kang, J.H.1    Irwin, D.J.2    Chen-Plotkin, A.S.3
  • 3
    • 84868585835 scopus 로고    scopus 로고
    • Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders
    • Hall S, Ohrfelt A, Constantinescu R, et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol 2012;69(11):1445-1452.
    • (2012) Arch Neurol , vol.69 , Issue.11 , pp. 1445-1452
    • Hall, S.1    Ohrfelt, A.2    Constantinescu, R.3
  • 5
    • 84871077687 scopus 로고    scopus 로고
    • Total CSF alpha-synuclein is lower in de novo Parkinson patients than in healthy subjects
    • Mollenhauer B, Trautmann E, Taylor P, et al. Total CSF alpha-synuclein is lower in de novo Parkinson patients than in healthy subjects. Neurosci Lett 2013;532:44-48.
    • (2013) Neurosci Lett , vol.532 , pp. 44-48
    • Mollenhauer, B.1    Trautmann, E.2    Taylor, P.3
  • 6
    • 77950223687 scopus 로고    scopus 로고
    • DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease
    • Hong Z, Shi M, Chung KA, et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2010;133(Pt 3):713-726.
    • (2010) Brain , vol.133 , pp. 713-726
    • Hong, Z.1    Shi, M.2    Chung, K.A.3
  • 7
    • 78649990079 scopus 로고    scopus 로고
    • Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease
    • Tokuda T, Qureshi MM, Ardah MT, et al. Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 2010;75(20):1766-1772.
    • (2010) Neurology , vol.75 , Issue.20 , pp. 1766-1772
    • Tokuda, T.1    Qureshi, M.M.2    Ardah, M.T.3
  • 8
    • 84862916400 scopus 로고    scopus 로고
    • Elevated levels of alpha-synuclein oligomer in the cerebrospinal fluid of drug-naive patients with Parkinson's disease
    • Park MJ, Cheon SM, Bae HR, Kim SH, Kim JW. Elevated levels of alpha-synuclein oligomer in the cerebrospinal fluid of drug-naive patients with Parkinson's disease. J Clin Neurol 2011;7(4):215-222.
    • (2011) J Clin Neurol , vol.7 , Issue.4 , pp. 215-222
    • Park, M.J.1    Cheon, S.M.2    Bae, H.R.3    Kim, S.H.4    Kim, J.W.5
  • 9
    • 82355191922 scopus 로고    scopus 로고
    • CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease
    • Sierks MR, Chatterjee G, McGraw C, Kasturirangan S, Schulz P, Prasad S. CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease. Integr Biol (Camb) 2011;3(12):1188-1196.
    • (2011) Integr Biol (Camb) , vol.3 , Issue.12 , pp. 1188-1196
    • Sierks, M.R.1    Chatterjee, G.2    McGraw, C.3    Kasturirangan, S.4    Schulz, P.5    Prasad, S.6
  • 10
    • 85017330543 scopus 로고    scopus 로고
    • Phosphorylated α -synuclein in Parkinson's disease: correlation depends on disease severity
    • Stewart T, Sossi V, Aasly J, et al. Phosphorylated α -synuclein in Parkinson's disease: correlation depends on disease severity. Acta Neuropathol 2015;31:3-7.
    • (2015) Acta Neuropathol , vol.31 , pp. 3-7
    • Stewart, T.1    Sossi, V.2    Aasly, J.3
  • 11
    • 72849127362 scopus 로고    scopus 로고
    • Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease
    • Compta Y, Marti MJ, Ibarretxe-Bilbao N, et al. Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease. Mov Disord 2009;24(15):2203-2210.
    • (2009) Mov Disord , vol.24 , Issue.15 , pp. 2203-2210
    • Compta, Y.1    Marti, M.J.2    Ibarretxe-Bilbao, N.3
  • 12
    • 84955726381 scopus 로고    scopus 로고
    • Neurodegenerative CSF markers in genetic and sporadic PD: classification and prediction in a longitudinal study
    • Brockmann K, Schulte C, Deuschle C, et al. Neurodegenerative CSF markers in genetic and sporadic PD: classification and prediction in a longitudinal study. Parkinsonism Relat Disord 2015;21:1427-1434.
    • (2015) Parkinsonism Relat Disord , vol.21 , pp. 1427-1434
    • Brockmann, K.1    Schulte, C.2    Deuschle, C.3
  • 13
    • 79960613150 scopus 로고    scopus 로고
    • Cerebrospinal fluid Tau/alpha-synuclein ratio in Parkinson's disease and degenerative dementias
    • Parnetti L, Chiasserini D, Bellomo G, et al. Cerebrospinal fluid Tau/alpha-synuclein ratio in Parkinson's disease and degenerative dementias. Mov Disord 2011;26(8):1428-1435.
    • (2011) Mov Disord , vol.26 , Issue.8 , pp. 1428-1435
    • Parnetti, L.1    Chiasserini, D.2    Bellomo, G.3
  • 14
    • 78349237282 scopus 로고    scopus 로고
    • CSF Abeta(42) and tau in Parkinson's disease with cognitive impairment
    • Montine TJ, Shi M, Quinn JF, et al. CSF Abeta(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord 2010;25(15):2682-2685.
    • (2010) Mov Disord , vol.25 , Issue.15 , pp. 2682-2685
    • Montine, T.J.1    Shi, M.2    Quinn, J.F.3
  • 15
    • 77955073900 scopus 로고    scopus 로고
    • Differential pattern of brain-specific CSF proteins tau and amyloid-beta in Parkinsonian syndromes
    • Sussmuth SD, Uttner I, Landwehrmeyer B, et al. Differential pattern of brain-specific CSF proteins tau and amyloid-beta in Parkinsonian syndromes. Mov Disord 2010;25(9):1284-1288.
    • (2010) Mov Disord , vol.25 , Issue.9 , pp. 1284-1288
    • Sussmuth, S.D.1    Uttner, I.2    Landwehrmeyer, B.3
  • 16
    • 58149469520 scopus 로고    scopus 로고
    • Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?
    • Ohrfelt A, Grognet P, Andreasen N, et al. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci Lett 2009;450(3):332-335.
    • (2009) Neurosci Lett , vol.450 , Issue.3 , pp. 332-335
    • Ohrfelt, A.1    Grognet, P.2    Andreasen, N.3
  • 17
    • 77958071837 scopus 로고    scopus 로고
    • CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study
    • Alves G, Bronnick K, Aarsland D, et al. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry 2010;81(10):1080-1086.
    • (2010) J Neurol Neurosurg Psychiatry , vol.81 , Issue.10 , pp. 1080-1086
    • Alves, G.1    Bronnick, K.2    Aarsland, D.3
  • 18
    • 47049100511 scopus 로고    scopus 로고
    • Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies
    • Parnetti L, Tiraboschi P, Lanari A, et al. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. Biol Psychiatry 2008;64(10):850-855.
    • (2008) Biol Psychiatry , vol.64 , Issue.10 , pp. 850-855
    • Parnetti, L.1    Tiraboschi, P.2    Lanari, A.3
  • 19
    • 79960353168 scopus 로고    scopus 로고
    • CSF alpha-synuclein, tau, and amyloid beta in Parkinson's disease
    • author's reply 81-83.
    • Shi M, Zhang J. CSF alpha-synuclein, tau, and amyloid beta in Parkinson's disease. Lancet Neurol 2011;10(8):681; author's reply 81-83.
    • (2011) Lancet Neurol , vol.10 , Issue.8 , pp. 681
    • Shi, M.1    Zhang, J.2
  • 20
    • 80054115170 scopus 로고    scopus 로고
    • Amyloid-beta and tau biomarkers in Parkinson's disease-dementia
    • Buongiorno M, Compta Y, Marti MJ. Amyloid-beta and tau biomarkers in Parkinson's disease-dementia. J Neurol Sci 2011;310(1-2):25-30.
    • (2011) J Neurol Sci , vol.310 , Issue.1-2 , pp. 25-30
    • Buongiorno, M.1    Compta, Y.2    Marti, M.J.3
  • 21
    • 84879411933 scopus 로고    scopus 로고
    • Combined dementia-risk biomarkers in Parkinson's disease: a prospective longitudinal study
    • Compta Y, Pereira JB, Rios J, et al. Combined dementia-risk biomarkers in Parkinson's disease: a prospective longitudinal study. Parkinsonism Relat Disord 2013;19(8):717-724.
    • (2013) Parkinsonism Relat Disord , vol.19 , Issue.8 , pp. 717-724
    • Compta, Y.1    Pereira, J.B.2    Rios, J.3
  • 22
    • 27144549543 scopus 로고    scopus 로고
    • Cognitive profile of patients with newly diagnosed Parkinson disease
    • Muslimovic D, Post B, Speelman JD, Schmand B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 2005;65(8):1239-1245.
    • (2005) Neurology , vol.65 , Issue.8 , pp. 1239-1245
    • Muslimovic, D.1    Post, B.2    Speelman, J.D.3    Schmand, B.4
  • 23
    • 27844469751 scopus 로고    scopus 로고
    • A systematic review of prevalence studies of dementia in Parkinson's disease
    • Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord 2005;20(10):1255-1263.
    • (2005) Mov Disord , vol.20 , Issue.10 , pp. 1255-1263
    • Aarsland, D.1    Zaccai, J.2    Brayne, C.3
  • 24
    • 8844233579 scopus 로고    scopus 로고
    • Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology
    • Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004;44(4):601-607.
    • (2004) Neuron , vol.44 , Issue.4 , pp. 601-607
    • Zimprich, A.1    Biskup, S.2    Leitner, P.3
  • 25
    • 8844266996 scopus 로고    scopus 로고
    • Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease
    • Paisan-Ruiz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004;44(4):595-600.
    • (2004) Neuron , vol.44 , Issue.4 , pp. 595-600
    • Paisan-Ruiz, C.1    Jain, S.2    Evans, E.W.3
  • 26
    • 84863287993 scopus 로고    scopus 로고
    • Cerebrospinal fluid amyloid beta and tau in LRRK2 mutation carriers
    • Aasly JO, Shi M, Sossi V, et al. Cerebrospinal fluid amyloid beta and tau in LRRK2 mutation carriers. Neurology 2012;78(1):55-61.
    • (2012) Neurology , vol.78 , Issue.1 , pp. 55-61
    • Aasly, J.O.1    Shi, M.2    Sossi, V.3
  • 27
    • 84856970318 scopus 로고    scopus 로고
    • DJ-1 and alphaSYN in LRRK2 CSF do not correlate with striatal dopaminergic function
    • Shi M, Furay AR, Sossi V, et al. DJ-1 and alphaSYN in LRRK2 CSF do not correlate with striatal dopaminergic function. Neurobiol Aging 2012;33(4):836e5-836e7.
    • (2012) Neurobiol Aging , vol.33 , Issue.4 , pp. 836e5-836e7
    • Shi, M.1    Furay, A.R.2    Sossi, V.3
  • 28
    • 84907162800 scopus 로고    scopus 로고
    • Elevated levels of cerebrospinal fluid alpha-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers
    • Aasly JO, Johansen KK, Bronstad G, et al. Elevated levels of cerebrospinal fluid alpha-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers. Front Aging Neurosci 2014;6:248.
    • (2014) Front Aging Neurosci , vol.6 , pp. 248
    • Aasly, J.O.1    Johansen, K.K.2    Bronstad, G.3
  • 29
    • 0042591659 scopus 로고    scopus 로고
    • status and recommendations
    • The Unified Parkinson's Disease Rating Scale (UPDRS)
    • The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 2003;18(7):738-750.
    • (2003) Mov Disord , vol.18 , Issue.7 , pp. 738-750
  • 30
    • 61449165975 scopus 로고    scopus 로고
    • Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results
    • Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23(15):2129-2170.
    • (2008) Mov Disord , vol.23 , Issue.15 , pp. 2129-2170
    • Goetz, C.G.1    Tilley, B.C.2    Shaftman, S.R.3
  • 31
    • 0014082977 scopus 로고
    • Parkinsonism: onset, progression and mortality
    • Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17(5):427-442.
    • (1967) Neurology , vol.17 , Issue.5 , pp. 427-442
    • Hoehn, M.M.1    Yahr, M.D.2
  • 32
    • 0025086894 scopus 로고
    • Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. the Parkinson Study Group
    • Jankovic J, McDermott M, Carter J, et al. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. the Parkinson Study Group. Neurology 1990;40(10):1529-1534.
    • (1990) Neurology , vol.40 , Issue.10 , pp. 1529-1534
    • Jankovic, J.1    McDermott, M.2    Carter, J.3
  • 33
    • 34447633928 scopus 로고    scopus 로고
    • Evolution of cognitive dysfunction in an incident Parkinson's disease cohort
    • Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain 2007;130(Pt 7):1787-1798.
    • (2007) Brain , vol.130 , pp. 1787-1798
    • Williams-Gray, C.H.1    Foltynie, T.2    Brayne, C.E.3    Robbins, T.W.4    Barker, R.A.5
  • 34
    • 84917679725 scopus 로고    scopus 로고
    • Phosphatases of α-synuclein, LRRK2, and tau: important players in the phosphorylation-dependent pathology of Parkinsonism
    • Taymans JM, Baekelandt V. Phosphatases of α-synuclein, LRRK2, and tau: important players in the phosphorylation-dependent pathology of Parkinsonism. Front Genet 2014;5:382.
    • (2014) Front Genet , vol.5 , pp. 382
    • Taymans, J.M.1    Baekelandt, V.2
  • 36
    • 78651440972 scopus 로고    scopus 로고
    • Leucine-rich repeat kinase 2 and alpha-synuclein: intersecting pathways in the pathogenesis of Parkinson's disease?
    • Greggio E, Bisaglia M, Civiero L, Bubacco L. Leucine-rich repeat kinase 2 and alpha-synuclein: intersecting pathways in the pathogenesis of Parkinson's disease? Mol Neurodegener 2011;6(1):6.
    • (2011) Mol Neurodegener , vol.6 , Issue.1 , pp. 6
    • Greggio, E.1    Bisaglia, M.2    Civiero, L.3    Bubacco, L.4
  • 37
  • 38
    • 0037118259 scopus 로고    scopus 로고
    • Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein
    • Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 2002;34(4):521-533.
    • (2002) Neuron , vol.34 , Issue.4 , pp. 521-533
    • Giasson, B.I.1    Duda, J.E.2    Quinn, S.M.3    Zhang, B.4    Trojanowski, J.Q.5    Lee, V.M.6
  • 39
    • 79957636327 scopus 로고    scopus 로고
    • Induction of intracellular tau aggregation is promoted by alpha-synuclein seeds and provides novel insights into the hyperphosphorylation of tau
    • Waxman EA, Giasson BI. Induction of intracellular tau aggregation is promoted by alpha-synuclein seeds and provides novel insights into the hyperphosphorylation of tau. J Neurosci 2011;31(21):7604-7618.
    • (2011) J Neurosci , vol.31 , Issue.21 , pp. 7604-7618
    • Waxman, E.A.1    Giasson, B.I.2
  • 41
    • 72849151978 scopus 로고    scopus 로고
    • When does Parkinson's disease begin?
    • Gaig C, Tolosa E. When does Parkinson's disease begin? Mov Disord. 2009;24(suppl 2):S656-S664.
    • (2009) Mov Disord. , vol.24 , pp. S656-S664
    • Gaig, C.1    Tolosa, E.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.